ETN101 / Etnova Therap - LARVOL DELTA

Etnova Therapeutics Announces Research Results of 'ETN101' at BioEurope 2024 [Google translation] (HIT News) - "Etnova Therapeutics...announced that it presented the non-clinical study results and phase 1 clinical progress of its hepatocellular carcinoma new drug candidate 'ETN101' at 'BIO EUROPE 2024' held in Stockholm, Sweden from the 4th to the 6th."

P1 data • Preclinical • Hepatocellular Cancer • Oncology • Solid Tumor

Etnova Therapeutics, US FDA Approves Phase 1 IND for Hepatocellular Carcinoma Targeting Anticancer Drug [Google translation] (Money Today) - "Etnova Therapeutics announced on the 16th that it had received approval for a phase 1 clinical trial (IND) for its hepatocellular carcinoma-targeting anticancer drug 'ETN101' from the U.S. Food and Drug Administration (FDA)...According to Etnova Therapeutics, the domestic phase 1 clinical trial, which began administering the first patient in February, is currently underway as a multi-center, open-label trial...'We are aiming to obtain the dose-limiting toxicity (DLT) results for cohort 3 by the end of this year.'"

IND • P1 data • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

The Comparative Metabolism of a Novel Hepatocellular Carcinoma Therapeutic Agent, 2,3-Diamino-N-(4-(benzo[d]thiazol-2-yl)phenyl)propanamide, in Human and Animal Hepatocytes. (PubMed, Metabolites) - "ETN101 remained stable in human CESs. In conclusion, this study provides comprehensive insights into the metabolic characteristics of ETN101, valuable for its toxicological and clinical development."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • CYP1A2 • NAT2

Etnova Therapeutics Announces ’ETN101’ Research at Interbiz [Google translation] (Pharm E Daily) - "Etnova Therapeutics announced on the 5th that it had presented a poster on the research progress of 'ETN101'...and held a technology commercialization meeting at the '22nd Interbiz Bio Partnering &Investment Forum 2024'...According to this poster presentation, in a study in which ETN101 was administered orally daily to an animal model of the disease created by transplanting human hepatocellular carcinoma, excellent efficacy was confirmed compared to the contro ldrug across the entire effective dose range. In the group administered with intermediate and high doses, complete remission was observed in all subjects, and no recurrence or metastasis occurred, demonstrating excellent tumor treatment efficacy...'The ongoing phase 1 clinical trial is being conducted as a multi-center, open-label 3+3 design in five cohorts,' and 'Cohort 2 is cruising without any particular adverse.'....'We expect to obtain the dose-limiting toxicity (DLT) results for Cohort 3 in the second half of this year.'"

P1 data • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Etnova Therapeutics Selected as a ‘Baby Unicorn’ Company by the Ministry of SMEs and Startups [Google translation] (News1 Korea) - "Etnova Therapeutics announced on the 28th that it was finally selected as a baby unicorn company for the 'Global Unicorn Project' hosted by the Ministry of SMEs and Startups...The Baby Unicorn Development Project, the first stage of the Global Unicorn Project, is a project to discover baby unicorn companies with proven innovative business models and growth potential and foster them into prospective unicorn companies with global competitiveness...Etnova Therapeutics believes that the excellent technology and differentiation of ETN101, a treatment candidate for unresectable advanced hepatocellular carcinoma currently being commercialized, are the reasons behind the selection of Baby Unicorn....Currently, phase 1 clinical trials are underway in Korea for patients with advanced hepatocellular carcinoma. In the second half of this year, the company will apply for a phase 1 clinical trial to the U.S. Food and Drug Administration (FDA) based on the results of phase 1..."

Commercial • New P1 trial • Trial status • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Preclinical antitumor efficacy of ETN101, a novel oral anticancer agent with Wnt/ß-catenin signaling inhibition, TME modulation, and VEGFR2 targeting for advanced hepatocellular carcinoma treatment. (ASCO 2024) - "During the 10 administrations of Nexavar and Lenvatinib, individuals who showed proliferated tumors persistently were selected, followed by the administration of ETN101. Due to lack of effective single drugs for advanced HCC patients, combination therapy is used clinically. We developed ETN101, a monotherapy that targets VEGFR2 and modulates the TME with the same mechanism as the combination therapy. ETN101 also showed excellent efficacy in preclinical study and secured a broad safety margin relative to the effective dose."

Metastases • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Oral Cancer • Solid Tumor

Etnova Therapeutics begins ‘ETN101’ biomarker research with Samsung Seoul Hospital [Google translation] (HIT News) - "Etnova Therapeutics...signed a contract on the 3rd to begin research on biomarker and target marker prediction for the hepatocellular cancer targeted anticancer drug 'ETN101' in collaboration with the research team of Professor Hong Jeong-yong and Dr. Yong-jae Shin of the Precision Medicine Innovation Research Institute at Samsung Seoul Hospital. revealed...This study aims to identify response factors that occur when ETN101 is administered, and will discover biomarkers and target markers for ETN101 through patient-derived xenograft (PDX) model and next-generation sequencing (NGS) analysis....Meanwhile, this study is being conducted with support from the National Research and Development Project (National Research Foundation of Korea Basic Research Project Research and Development Project) for which Etnova Therapeutics was selected as the lead research institute. The project performance period is from June 2023 to 2026. Until February."

Licensing / partnership • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Etnova Therapeutics Corp.

Metastases • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Etnova Therapeutics begins administering hepatocellular cancer targeted anticancer drug 'ETN101' to patients [Google translation] (HIT News) - "Interim results of phase 1 domestic clinical trials of ETN101 expected in the second half of this year...Etnova Therapeutics...announced on the 8th that it has started administering the first patient in the phase 1 clinical trial of 'ETN101 (development code name)', a new drug candidate for oral targeted anticancer drug for advanced hepatocellular carcinoma...Etnova Therapeutics is conducting clinical trials on up to 30 patients....Etnova Therapeutics is conducting research to expand the indications for ETN101 to develop innovative new drugs for incurable diseases, and plans to begin global clinical preparations starting with submission of IND to the U.S. Food and Drug Administration (FDA) in the second half of this year."

IND • P1 data • Trial status • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Etnova Therapeutics, hepatocellular cancer target anticancer drug approved for phase 1 clinical trial in Korea [Google translation] (HIT News) - "Etnova Therapeutics...announced on the 17th that it had received approval from the Ministry of Food and Drug Safety on the 11th for the phase 1 clinical trial plan (IND) of 'ETN101 (development code name)', a target anti-cancer drug for hepatocellular carcinoma....'A company official said, 'The purpose of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of ETN101 in patients with advanced hepatocellular carcinoma.'"

New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases. (PubMed, Cancers (Basel)) - "Approved first-line treatments include sorafenib, lenvatinib, and a combination of atezolizumab and bevacizumab; however, they do not cure HCC. MBP-11901 induced anticancer effects by targeting the signaling mechanisms of FLT3, VEGFR2, c-KIT, and PDGFRβ. MBP-11901 is suggested as a novel therapeutic agent for the treatment of advanced or unresectable liver cancer."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • FLT3 • KDR • KIT • PDGFRB